Skip to content
Menu

10x Genomics, Inc. TXG

Full chart Compare
Set alert

Price alert · TXG

All alert types
52.93 USD -4.45 (-7.76%)

As ofNov 20, 2026, 1:25 PM EST

52.24 Day range 56.44
15.18 52-week range 102.81
YTD
+224.52%
1 year
+221.57%

5D -3.91 (-6.93%)

5560MonTueWedThuFri52.51
Market cap
6.97B
Revenue (ttm)
618.58M
Profit margin
-10.84%
EPS (ttm)
-0.52
Shares out
121.46M
Forward P/E
662.05
YTD return
+224.52%
1-year return
+221.57%
50-day average
73.38
200-day average
43.12
Volume
1.13M
Avg volume
3.36M
Open
56.44
Previous close
57.38
Day's range
52.24 – 56.44
52-week range
15.18 – 102.81
Beta
2.03
Analysts
Buy
Price target
68.14 (+28.7%)
Earnings date
Feb 11, 2027

Key statistics

Enterprise value
7.01B
Price / sales
12.20
Price / book
9.00
Revenue growth
1.10%
Free cash flow
122.82M
Total cash
575.68M
Total debt
75.79M
Return on equity
-8.27%
Short % of float
13.85%

Fundamental scorecard

7 of 25 checks passed on TXG’s reported financials

ValueGrowthProfitabilityHealthDividend

7of 25 checks passed

  • Value 0 of 5
  • Growth 2 of 5
  • Profitability 1 of 5
  • Financial health 4 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
TXG Revenue — quarterly 150.67M
TXG Net income — quarterly -19.43M
TXG EPS — quarterly -0.15

Earnings

TXG recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 11, 2027Dec 30, 2026-0.20———
Nov 5, 2026Sep 30, 2026-0.267-0.15+0.12+43.82%
Aug 6, 2026Jun 30, 2026-0.24308-0.14+0.10+42.41%
May 7, 2026Mar 31, 2026-0.29-0.10+0.19+65.52%
Feb 12, 2026Dec 31, 2025-0.19-0.13+0.06+31.58%
Nov 6, 2025Sep 30, 2025-0.07-0.22-0.15-214.29%

Upgrades / downgrades

TXG analyst upgrades and downgrades
DateFirmActionFromTo
Nov 9, 2026JP MorganmainNeutralNeutral
Nov 9, 2026BarclaysmainOverweightOverweight
Nov 6, 2026UBSmainNeutralNeutral
Nov 6, 2026CitigroupmainNeutralNeutral
Nov 6, 2026StifelmainBuyBuy
Oct 13, 2026TD CowenmainHoldHold

About 10x Genomics, Inc.

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on TXG — it syncs with the Stock Master app.

Insider holders

TXG insider holders
InsiderRelationLatest transactionDateShares held
HINDSON BENJAMIN JPresidentSaleAug 23, 2026488,182
KOSARAJU SRIDHARDirectorStock Award(Grant)Jun 3, 202668,278
MATEO ALAN V.DirectorStock Award(Grant)Jun 3, 202685,877
POPOVITS KIMBERLY JDirectorStock Award(Grant)Jun 3, 202637,445
SAXONOV SERGE WILSONChief Executive OfficerSaleSep 21, 20261,335,170
STUELPNAGEL JOHN RDirectorSaleSep 2, 2026328,436

Institution ownership

TXG institution ownership
Holder% heldSharesValueReported
FMR, LLC14.93%18,138,6991.04BSep 29, 2026
Price (T.Rowe) Associates Inc14.38%17,470,8961.00BSep 29, 2026
Blackrock Inc.9.53%11,574,445664.14MSep 29, 2026
ARK Investment Management, LLC5.16%6,272,998359.94MSep 29, 2026
Vanguard Portfolio Management LLC4.87%5,914,697339.39MSep 29, 2026
Vanguard Capital Management LLC4.44%5,393,690309.49MSep 29, 2026

Fund ownership

TXG fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.91%3,528,683202.48MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.50%3,032,629174.01MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.10%2,548,523146.23MJun 29, 2026
ARK ETF Trust-ARK Genomic Revolution ETF2.09%2,535,217145.47MOct 30, 2026
ARK ETF Trust-ARK Innovation ETF1.81%2,198,294126.14MOct 30, 2026
Fidelity Select PORT.s-Select Medical Technology and Devices PORT.1.37%1,670,00095.82MSep 29, 2026